Stockscreener 앱 받기
2.99
2.40%
0.07
시간 외 거래:
3.00
0.010
+0.33%
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Context will show preclinical CT-202 tumor data at April cancer meeting - Stock Titan
Loss Report: Is Context Therapeutics Inc stock risky to hold now2026 Dividend Review & Expert Curated Trade Ideas - baoquankhu1.vn
HR Positive/ HER2 Negative Breast Cancer Clinical Trial - openPR.com
HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
CNTX PE Ratio & Valuation, Is CNTX Overvalued - Intellectia AI
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data - MarketBeat
Context Therapeutics Inc. Files 8-K and Certificate of Correction to Amended and Restated Certificate of Incorporation (March 11, 2026) - Minichart
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes - TipRanks
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Quarterly Earnings: How does Context Therapeutics Inc compare to its peersWeekly Profit Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Context Therapeutics (CNTX) to Release Earnings on Thursday - MarketBeat
Movement Recap: Can Context Therapeutics Inc stock double in the next yearPortfolio Update Report & Stock Market Timing Techniques - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market Expected - openPR.com
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Context Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ADXN.SW Addex Therapeutics Ltd (SIX) 09 Mar 2026: Earnings due; liquidity and forecast to watch - Meyka
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference - MarketBeat
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy - Cantech Letter
CNTX SEC FilingsContext Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
CNTX: Advancing three T-cell engager programs in solid tumors with key data milestones ahead - TradingView
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CNTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat
CNTX Should I Buy - Intellectia AI
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - TipRanks
Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan
Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World
Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy" - MarketBeat
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Context Therapeutics (CNTX) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
Context Therapeutics (CNTX) awards 270,000 stock options to Chief Legal Officer - Stock Titan
CFO at Context Therapeutics (CNTX) receives 275,000-share stock option grant - Stock Titan
Context Therapeutics (CNTX) CEO granted 815,000 stock options - Stock Titan
Context Therapeutics (CNTX) awards 290,000 stock options to Chief Medical Officer - Stock Titan
What is Context Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Target Return Focused Stock Picks - mfd.ru
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN
Is Context Therapeutics Inc. a potential multi bagger2025 Technical Patterns & Smart Money Movement Tracker - mfd.ru
Shorts Report: Is H2O America stock forming a triangle patternQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Geopolitics Watch: Whats the fair value of TMHC stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Profit Recap: What is Context Therapeutics Incs book value per shareJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Fund Flows: How does Context Therapeutics Inc perform in inflationary periodsEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Great Point reveals 5.1% Context Therapeutics (CNTX) stake in 13G/A - Stock Titan
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
Earnings Report: Is Klaviyo Inc attractive for institutional investorsLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
How cyclical is Context Therapeutics Inc.’s revenue streamProfit Target & Real-Time Buy Signal Notifications - mfd.ru
Bank Watch: Does ABRPRD have pricing powerPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru
Will AGF A S (5IN) stock return to pre crash levelsQuarterly Growth Report & Smart Swing Trading Alerts - mfd.ru
ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka
Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail
SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka
1.20%
0.06%
자본화:
|
볼륨(24시간):